.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Johnson and Johnson
Accenture
Citi
UBS
Colorcon
Moodys
Baxter
Argus Health
Cantor Fitzgerald

Generated: November 21, 2017

DrugPatentWatch Database Preview

MALARONE Drug Profile

« Back to Dashboard

Which patents cover Malarone, and what generic Malarone alternatives are available?

Malarone is a drug marketed by Glaxosmithkline and is included in one NDA.

The generic ingredient in MALARONE is atovaquone; proguanil hydrochloride. There are sixteen drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the atovaquone; proguanil hydrochloride profile page.

Pharmacology for MALARONE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline
MALARONE
atovaquone; proguanil hydrochloride
TABLET;ORAL021078-001Jul 14, 2000ABRXYesYes► Subscribe► Subscribe► Subscribe
Glaxosmithkline
MALARONE PEDIATRIC
atovaquone; proguanil hydrochloride
TABLET;ORAL021078-002Jul 14, 2000ABRXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: MALARONE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline
MALARONE
atovaquone; proguanil hydrochloride
TABLET;ORAL021078-001Jul 14, 2000► Subscribe► Subscribe
Glaxosmithkline
MALARONE
atovaquone; proguanil hydrochloride
TABLET;ORAL021078-001Jul 14, 2000► Subscribe► Subscribe
Glaxosmithkline
MALARONE
atovaquone; proguanil hydrochloride
TABLET;ORAL021078-001Jul 14, 2000► Subscribe► Subscribe
Glaxosmithkline
MALARONE
atovaquone; proguanil hydrochloride
TABLET;ORAL021078-001Jul 14, 2000► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for MALARONE

Drugname Dosage Strength RLD Submissiondate
atovaquone and proguanil hydrochlorideTablets62.5 mg/25 mgMalarone9/14/2010
atovaquone and proguanil hydrochlorideTablets250 mg/100 mgMalarone4/3/2009
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Cantor Fitzgerald
Chinese Patent Office
Fish and Richardson
Daiichi Sankyo
Teva
US Army
Citi
McKinsey
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot